By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Novo Nordisk launches Wegovy in India, expanding GLP-1 obesity drug market. The product competes with Eli Lilly's Mounjaro ...